MIRA secures board approval to buy SKNY Pharmaceuticals
The strategic decision follows thorough independent valuations of both entities, with the merger contingent upon approval from shareholders of both companies. Moore Financial Consulting conducted a third-party analysis
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.